Subscribe 600$/product give away!
Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

CINQAIR- reslizumab injection, solution, concentrate

  1. Patient Information
  2. Manufactured By:

Patient Information 

See FDA approved patient labeling (Patient Information).


Inform patients that hypersensitivity reactions, including anaphylaxis, have occurred with administration of CINQAIR. Educate patients on the signs and symptoms of hypersensitivity reactions and anaphylaxis (e.g., skin or mucosal involvement, airway compromise, reduced blood pressure). Instruct patients to contact their healthcare professional immediately if they experience symptoms of an allergic reaction after they have received their infusion of CINQAIR[see Warnings and Precautions (5.1)].

Not for Acute Symptoms or Deteriorating Disease

Inform patients that CINQAIR does not treat acute asthma symptoms or acute exacerbations. Inform patients to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with CINQAIR[see Warnings and Precautions (5.2)].


Counsel CINQAIR-treated patients about the risk of malignancies[see Warnings and Precautions (5.3)].

Reduction of Corticosteroid Dosage

Inform patients not to discontinue systemic or inhaled corticosteroids except under the direct supervision of a physician. Inform patients that reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy[see Warnings and Precautions (5.4)].

Manufactured By: 

Teva Respiratory, LLC

Frazer, PA 19355

U.S. License Number 2047

US Patent RE39,548 and 6,056,957

2019 Teva Respiratory, LLC


Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources | Sitemap
2017 © Copyright Questions?
Please contact: